Lipoprotein glomerulopathy is a pathological condition characterized by lipid accumulation in the glomerular capillaries that has been associated with the presence of rare mutants of apolipoprotein E (ApoE). We describe a 51-year-old Italian patient presenting Type III hyperlipidemia and proteinuria in whom renal biopsy showed capillary ectasia and intraluminal lipid deposits, suggesting the diagnosis of lipoprotein glomerulopathy. The patient, who had elevated plasma ApoE level, was found to be heterozygous for a mutation in ApoE (Arg150Cys), designated apoEMODENA. This mutation induces the formation of ApoE dimers that are detectable under non-reducing conditions. Treatment with hypolipidemic drugs did not result in a complete remission of the proteinuria and was accompanied by a slow but progressive worsening of renal function with the persistence of intracapillary lipid thrombi. The introduction of low-density lipoprotein aphaeresis combined with a more aggressive lipid lowering and antihypertensive therapy resulted in the remission of proteinuria and a substantial improvement of renal function. Switching from low-density lipoprotein aphaeresis to plasma filtration did not result in an equivalent control of renal damage. The patient died of intracranial hemorrhage during an acute episode of malignant hypertension.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859823PMC
http://dx.doi.org/10.4137/CCRep.S12209DOI Listing

Publication Analysis

Top Keywords

lipoprotein glomerulopathy
12
remission proteinuria
8
renal function
8
low-density lipoprotein
8
lipoprotein aphaeresis
8
lipoprotein
5
glomerulopathy associated
4
associated mutation
4
mutation apolipoprotein
4
apolipoprotein lipoprotein
4

Similar Publications

Apolipoprotein E (apoE) is a key apoprotein in lipid transport and is susceptible to genetic mutations. ApoE variants have been studied for four decades and more than a hundred of them have been reported. This paper presents an up-to-date review of the function and structure of apoE in lipid metabolism, the E2, E3, and E4 isoforms, the APOE gene, and various pathologies, such as familial type III hyperlipidemia and lipoprotein glomerulopathy, caused by apoE variants.

View Article and Find Full Text PDF

First patient diagnosed with lipoprotein glomerulopathy and Alport syndrome.

Nephrology (Carlton)

December 2024

Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Article Synopsis
  • - Alport syndrome (AS) is a common genetic kidney disorder resulting from mutations in COL4A3, COL4A4, and COL4A5 genes, leading to abnormal collagen IV structure and function.
  • - Lipoprotein glomerulopathy (LPG) is another inherited condition linked to mutations in the APOE gene, affecting lipid metabolism.
  • - A case is reported of an 11-year-old girl with both AS and LPG, exhibiting various symptoms and laboratory findings, and genetic tests identified specific pathogenic variants; the study highlights the need for early renal biopsy and whole-exome sequencing for accurate diagnosis.
View Article and Find Full Text PDF

A 33-year-old Japanese man was admitted for possible kidney disease because of massive proteinuria. Laboratory findings were characterized by marked urinary protein of 4.7 g/day and high-serum triglyceride levels of 266 mg/dL.

View Article and Find Full Text PDF

Background: Lipoprotein glomerulopathy (LPG) is a apolipoprotein E (ApoE)-related glomerular disease and has been associated with type III hyperlipidemia. Without appropriate treatment, chronic kidney disease (CKD) caused by LPG progresses, and approximately half of the patients develop end-stage kidney disease within 1-27 years of disease onset. However, few studies have highlighted the clinical course of cardiovascular diseases (CVDs) in patients with LPG.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!